-
Mashup Score: 4Navigating the Landscape of Precision Medicine in Gastric Cancer: FGFR2b Protein Overexpression as an Emerging Biomarker - 10 day(s) ago
Gastric and gastroesophageal junction (G/GEJ) cancers, otherwise known as stomach cancer, is the fourth leading cause of cancer-related death worldwide, with the highest incidence rates occurring in Eastern Asia and Eastern Europe. Exploring the role of FGFR2b protein overexpression in gastric cancer represents an exciting potential for targeted therapy.
Source: www.amgen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 1Advancing Oncology at the Speed of Life | Amgen Oncology - 11 day(s) ago
At Amgen we are committed to changing the course of cancer treatment for more than 40 years. Learn about all of the different Amgen Oncology web propoerties and resources that Amgen has to offer.
Source: www.amgenoncology.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 4HEAL Collaborative: Health Education Advocacy Learning - 22 day(s) ago
HEAL Collaborative is a community-based organization with a mission to make communities of color healthier through healthcare education and advocacy.
Source: healcollaborative.orgCategories: General Medicine News, PayerTweet
-
Mashup Score: 1Home - 1 month(s) ago
Biomarkers are the key to treating stomach cancer. Test first. Because the best treatment for your stomach cancer can be individualized.
Source: testyourbiomarkers.orgCategories: General Medicine News, PayerTweet
-
Mashup Score: 3Home - 1 month(s) ago
Learn how DLL3 and T-cell engager technology together have the potential to address unmet needs in SCLC and high-grade neuroendocrine cancers.
Source: www.dll3possibilities.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 15Jean-Charles Soria Elected to AACR Board of Directors - 1 month(s) ago
Jean-Charles Soria, Amgen’s senior vice president of Oncology within Global Development, has been elected to the American Association for Cancer Research (AACR) Board of Directors for the 2024-2027 term.
Source: wwwext.amgen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 0
CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.
Source: www.curetoday.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 6Call-on Congress | Fight Colorectal Cancer - 2 month(s) ago
We demand that policymakers act. We can’t afford to wait, lives are at stake today! Join us in D.C — we need to fight for more.
Source: fightcolorectalcancer.orgCategories: General Medicine News, PayerTweet
-
Mashup Score: 6Call-on Congress | Fight Colorectal Cancer - 2 month(s) ago
We demand that policymakers act. We can’t afford to wait, lives are at stake today! Join us in D.C — we need to fight for more.
Source: fightcolorectalcancer.orgCategories: General Medicine News, PayerTweet
-
Mashup Score: 5Home - 2 month(s) ago
Learn how DLL3 and T-cell engager technology together have the potential to address unmet needs in SCLC and high-grade neuroendocrine cancers.
Source: www.dll3possibilities.comCategories: General Medicine News, PayerTweet
How can we personalize gastric cancer care? At @Amgen, we’re exploring the full potential of #FGFR2b as a target 🎯 for new therapies. 🔗Learn more about FGFR2b: https://t.co/MBdteNkhIK https://t.co/7w7ZDe6rbm